Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.80
Ask: 3.84
Change: 0.09 (2.43%)
Spread: 0.04 (1.053%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.71
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PHC949 product registration submitted to the EPA

31 Jan 2022 07:00

RNS Number : 0579A
Plant Health Care PLC
31 January 2022
 

RNS

 

 

31 January 2022

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

PHC949 submitted for product registration in the USA

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, announces it has submitted a new application to the US Environmental Protection Agency (EPA) for registration of its novel peptide product, PHC949, for the control of damaging soil nematodes.

 

Highlights

- PHC949 is the second new product from Plant Health Care's PREtec (Vaccines for PlantsTM) technology platform; the Company plans one major new launch every year.

- The Company is targeting PHC949 against nematodes (soil pests), a market forecast to be worth $1.6 billion globally by 2025; these pests reduce crop yields by some $100 billion annually.

- In the USA, PHC949 is being co-developed with Wilbur-Ellis for nematode control in high-value specialty crops. Wilbur-Ellis, a $3.4bn distributor of crop inputs, plans to launch the product in the second half of 2023, soon after registration by the EPA.

- Field trials of PHC949 in the USA show outstanding control of nematodes; for example, in peppers PHC949 increased marketable yield by about 3,265 lbs/acre, worth an extra $2,070/acre.

- Field trials are also underway demonstrating the value of PHC949 in soybeans and other crops in the US and Brazil.

- The Company expects global sales of PHC949 to reach into the tens of millions of dollars over the long-term and to become a significant value driver for the Company.

 

Overview

PREtec peptides (Vaccines for Plants) represent a novel class of technology which stimulates the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and increasing yields. PREtec peptides support conventional farming to become more sustainable. The Company has invested more than $25 million in inventing and developing the PREtec platform over the last eight years and now plans to achieve at least one major launch of a PREtec product into a major market, every year.

 

Nematode pests are found in farmland worldwide and cause extensive damage to crops, reducing yields by approximately $100 billion annually. In California alone, nematode damage results in approximately $1.6 billion in annual yield losses for almond growers.

 

PHC949 enables plants to resist nematode infestation and leads to increased plant vigor and yield in a variety of crops. Unlike traditional chemical soil fumigants used to control nematodes, PHC949 leaves beneficial soil organisms unharmed.

 

The Company has now made a regulatory submission to the Environmental Protection Agency (EPA) for the use of PHC949 to control nematodes on a wide range of crops. The EPA's evaluation process is expected to take approximately 18 months.

 

The Company is working actively with Wilbur-Ellis to ready the product for launch, soon after the EPA issues commercial regulatory permits.

 

Plans are also underway to submit PHC949 in late 2022 for registration in Brazil, setting the stage for commercialization of PHC949 for use on soybeans in Brazil in 2024.

 

Chris Richards, CEO of Plant Health Care said; "We are pleased to have achieved this critical milestone in bringing PHC949 to market and are looking forward to commercial launch in the US after regulatory approval in 2023.

 

"Given the large number of chemical nematicides that have been withdrawn from the market by regulators because of environmental concerns, farmers are clamoring for sustainable solutions to protect their crops. I am confident therefore that PHC949 will be a valuable tool for growers, offering a cost-effective and environmentally friendly way to protect their crops from destructive nematodes.

 

"The regulatory submission of PHC949 follows the introduction of Saori® in Brazil during 2021 and the planned launch of PHC279 in the USA following regulatory approval later this year. With the submission of PHC949 in the USA, we are on target to achieve at least one major launch of a PREtec product, every year. We are excited about the potential for products based on our 'Vaccines for Plants' PREtec peptides, which are targeting markets valued in total at $5 billion."

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, CEO

+1 919 926 1600

 

Arden Partners plc - Nomad & Joint Broker

John Llewellyn-Lloyd / Antonio Bossi

+44 (0) 20 7614 5900

 

Cenkos Securities plc - Joint Broker

Neil McDonald / Peter Lynch

+44 (0) 20 7391 8900

 

Vox Markets - Digital Investor Relations

Paul Cornelius / Kat Perez

+44 (0) 7866 384707

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. Find out more at Vox Markets and the company website: www.planthealthcare.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEBLFXLFLEBBX
Date   Source Headline
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement
28th Nov 20187:00 amRNSNew Technology Update
21st Nov 20187:00 amRNSPlant Health Care ProAct® Wins Top Industry Award
19th Nov 20187:00 amRNSPlant Health Care to present at Mello London

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.